{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:38:49Z","timestamp":1774330729464,"version":"3.50.1"},"reference-count":114,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pediatric pulmonary hypertension (PAH) is a rare disease that carries a poor prognosis if left untreated. Although there are published guidelines for the treatment of children with pulmonary hypertension, due to the limited number of robust pediatric clinical trials, recommendations are often based on limited data or clinical experience. Furthermore, many practical aspects of care, particularly for the pediatric patient, are learned through experience and best navigated with a multidisciplinary team. While newer PAH therapies have been approved for adults, there is still limited but expanding experience in pediatrics. This new information will help improve the targets of goal\u2010oriented therapy. Lastly, this review highlights practical aspects in the use of the different therapies available for the treatment of pediatric pulmonary hypertension.<\/jats:p>","DOI":"10.1002\/ppul.25101","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T17:41:47Z","timestamp":1601574107000},"page":"593-613","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children"],"prefix":"10.1002","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3419-2613","authenticated-orcid":false,"given":"Charissa W.","family":"Kam","sequence":"first","affiliation":[{"name":"Department of Pharmacy Texas Children's Hospital Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadel E.","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Department of Pulmonology,\u00a0Baylor College of Medicine Texas Children's Hospital Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.02.575"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.21693\/1933-088X-17.4.153"},{"issue":"4","key":"e_1_2_12_5_1","first-page":"44","article-title":"Diagnosis, evaluation and treatment of pulmonary arterial hypertension in children","volume":"5","author":"Frank BS","year":"2018","journal-title":"Children (Basel)"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000329"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-309103"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0052-2"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1013937"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.03.575"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01916-2018"},{"key":"e_1_2_12_12_1","unstructured":"MullenMPandKulikT ed.Pulmonary Hypertension in Children: Management and Prognosis. Waltham MA;2019.https:\/\/www.uptodate.com\/contents\/pulmonary-hypertension-in-children-management-and-prognosis. Accessed August 7 2020."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2019.1565998"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035092"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-3225"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.3435"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-4060"},{"key":"e_1_2_12_19_1","unstructured":"Actelion Pharmaceuticals ed.Tracleer [package insert]. San Francisco CA;2017."},{"key":"e_1_2_12_20_1","first-page":"151","volume-title":"Pulmonary hypertension: A patient's survival guide","author":"Benza R","year":"2016"},{"key":"e_1_2_12_21_1","unstructured":"Silvergate Pharmaceuticals ed.Katerzia [package insert]. Greenwood Village CO;2019."},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0904473"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.016667"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005698"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.09.067"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050208"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-012-0180-4"},{"issue":"1","key":"e_1_2_12_28_1","first-page":"7","article-title":"Oral tadalafil in children with pulmonary arterial hypertension","volume":"66","author":"Shiva A","year":"2016","journal-title":"Drug Res (Stuttg)"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1354832"},{"key":"e_1_2_12_30_1","unstructured":"US Department of Health and Human Services.Approved drug products with therapeutic equivance evaluations. 40th ed.;2020. Accessed 25 August\u00a02020."},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00005-5"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03532.x"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5105-389"},{"key":"e_1_2_12_34_1","unstructured":"Bosentan REMS program.https:\/\/www.bosentanremsprogram.com\/BosentanUI\/faqs.u%23. Updated 2019. Accessed\u00a0October\u00a030 \u00a02019."},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22555"},{"key":"e_1_2_12_36_1","unstructured":"Long\u2010term ambrisentan extension study for pediatric patients who participated in AMB112529.ClinicalTrials.govidentifier: NCT01342952 Web site.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01342952. Updated 2020. Accessed June 7 \u00a02020."},{"key":"e_1_2_12_37_1","unstructured":"Gilead SciencesI ed.Letairis [package insert]. Foster City CA;2019."},{"key":"e_1_2_12_38_1","unstructured":"BrooksMFDA approvesletairis(ambrisentan) generics for PAH.https:\/\/www.medscape.com\/viewarticle\/911166?nlid=129138_3901&src=wnl_newsalrt_190401_MSCPEDIT&uac=245402AT&impID=1925156&faf=1. Accessed October 1 2019."},{"key":"e_1_2_12_39_1","unstructured":"Pulmonary Hypertension Association. PHA advocacy success: 2 ambrisentan REMS programs to merge.https:\/\/phassociation.org\/pha-advocacy-success-2-ambrisentan-rems-programs-to-merge\/#:~:text=Thanks%20to%20the%20Pulmonary%20Hypertension close%20permanently%20Friday%2C%20May%2029.\u00a0Accessed June 2 2020."},{"key":"e_1_2_12_40_1","unstructured":"A study to assess whether macitentan delays disease progression in children with pulmonary arterial hypertension (PAH) (TOMORROW).ClinicalTrials.govidentifier: NCT02932410 Web site.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02932410. Accessed October 25 2019."},{"key":"e_1_2_12_41_1","unstructured":"Clinical study to assess the long\u2010term safety and tolerability of ACT 064992 in patients with symptomatic pulmonary arterial hypertension (SERAPHIN OL).ClinicalTrials.govidentifier: NCT00667823 Web site.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00667823. Accessed June 7 2020."},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1086\/674762"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200408000-00010"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/emj.2007.046250"},{"issue":"16","key":"e_1_2_12_45_1","first-page":"1","article-title":"Multiple intravenous infusions phase 1b: practice and training scan","volume":"12","author":"Cassano\u2010Piche A","year":"2012","journal-title":"Ont Health Technol Assess Ser"},{"key":"e_1_2_12_46_1","unstructured":"United Therapeutics Corp ed.Remodulin [package insert]. Research Triangle Park NC;2002."},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.09.119"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.03.067"},{"key":"e_1_2_12_49_1","unstructured":"Remodulin. REMODULIN SPmix PROGR; AM FOR IV REMODULIN PATIENTS.https:\/\/www.remodulinpro.com\/resources\/specialty-pharmacy. Accessed June 2 2019."},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2010.06.013"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2010.09.025"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2013.01.1055"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003261343"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004264638"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000674"},{"key":"e_1_2_12_56_1","first-page":"75","volume-title":"Pulmonary hypertension: A patient's survival guide","author":"Liu J","year":"2016"},{"key":"e_1_2_12_57_1","unstructured":"Implantable system for remodulin post\u2010approval study (ISR PAS).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03833323. Accessed June 7 2020."},{"key":"e_1_2_12_58_1","unstructured":"United Therapeutics Corp. In development\u2014the implantable system for remodulin\u00ae.https:\/\/www.remodulin.com\/pump-options\/implantable-pump\/. Accessed June 7 2020."},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045894018788846"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24707"},{"key":"e_1_2_12_61_1","unstructured":"United Therapeutics Corp. United therapeutics and DEKA announce additional FDA clearance related to the unity subcutaneous delivery system for remodulin\u00ae.https:\/\/ir.unither.com\/news\/press-releases\/press-release-details\/2020\/United-Therapeutics-and-DEKA-Announce-Additional-FDA-Clearance-Related-to-the-Unity-Subcutaneous-Delivery-System-for-Remodulin\/default.aspx. Accessed August 25 2020."},{"key":"e_1_2_12_62_1","unstructured":"Remodulin. Remunity.https:\/\/www.remodulin.com\/91pump-options\/remunity\/. Accessed August 25 \u00a02020."},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019856471"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019862138"},{"key":"e_1_2_12_65_1","unstructured":"United Therapeutics Corp ed.Orenitram [package insert]. Research Triangle Park NC;2013."},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2016.06.019"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1086\/690109"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000842"},{"key":"e_1_2_12_69_1","unstructured":"United Therapeutics Corp ed.Tyvaso [package insert]. Research Triangle; Park NC;2009."},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.07.037"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000001188"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0409-0"},{"key":"e_1_2_12_73_1","unstructured":"Actelion Pharmaceuticals ed.Ventavis [package insert]. San Francisco CA;2019."},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2007.08.084"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.031"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1086\/685080"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160798"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019876545"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-017-1677-7"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1047951119001082"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.03.029"},{"key":"e_1_2_12_83_1","unstructured":"A clinical study of to confirm the doses of selexipag in children with pulmonary arterial hypertension.ClinicalTrials.govidentifier: NCT03492177 Web site.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03492177. Accessed June 7 2020."},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00081"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24442"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-307832"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217743123"},{"key":"e_1_2_12_88_1","unstructured":"Riociguat in children with pulmonary arterial hypertension (P108AH) (PATENT\u2010CHILD).ClinicalTrials.govidentifier: NCT02562235 Web site.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02562235. Accessed June 7 2020."},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15215"},{"key":"e_1_2_12_90_1","unstructured":"CondrenM BriarsL BenavidesS GildonBLPractice management issues in pediatric ambulatory care. PPAG Annual Conference;2018."},{"key":"e_1_2_12_91_1","unstructured":"Center for Drug Evaluation and Research. Compounded drug products that are essentially copies of a commercially\u00a0available drug product under section 503A of the federal food drug and cosmetic act guidance for industry;2018."},{"issue":"5","key":"e_1_2_12_92_1","first-page":"66","article-title":"Pediatric compounding pharmacy: taking on the responsibility of providing quality customized prescriptions","volume":"6","author":"Heitman T","year":"2019","journal-title":"Children (Basel)"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-013-0005-9"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-2173"},{"key":"e_1_2_12_95_1","first-page":"201","volume-title":"Pulmonary Hypertension: A Patient's Survival Guide","author":"Wilcox D","year":"2016"},{"key":"e_1_2_12_96_1","unstructured":"Pfizer ed.Revatio [package insert]. New York City NY;2012."},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.082826"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.5.719"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2018.09.003"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000496"},{"key":"e_1_2_12_101_1","unstructured":"MarkinCJ DiwanJ\u00a0Transition from oral selexipag to subcutaneous treprostinil in a patient with scleroderma\u2010related pulmonary arterial hypertension. PHPN Symposium;\u00a02017."},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-017-0480-9"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1951"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019862167"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019843665"},{"key":"e_1_2_12_106_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019898032"},{"key":"e_1_2_12_107_1","doi-asserted-by":"crossref","unstructured":"KimJ SerpaE MarkinC DiwanJA successful rapid transition from epoprostenol to selexipag monotherapy in a patient with idiopathic pulmonary arterial hypertension.Chest Annual Meeting;2018.","DOI":"10.1016\/j.chest.2018.08.910"},{"issue":"6","key":"e_1_2_12_108_1","first-page":"865","article-title":"Stability of nifedipine in two oral suspensions stored at two temperatures","volume":"42","author":"Nahata MC","journal-title":"J Am Pharm Assoc"},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/53.18.2179"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23503"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp120364"},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110034"},{"key":"e_1_2_12_113_1","unstructured":"Actelion Ltd. Data on file.2017."},{"key":"e_1_2_12_114_1","unstructured":"HabibNFJThree\u2010A\u2010day dosing of selexipag in the treatment of pulmonary arterial hypertension: A case series.CASE REPORTS IN PULMONARY VASCULAR MEDICINE I. May 1 2018:Presented at the American Thoracic Society International Conference May 18\u201023 2018. San Diego California. Poster 1035."},{"key":"e_1_2_12_115_1","unstructured":"Actelion Pharmaceuticals ed.Uptravi [package insert]. San Francisco CA;2015."}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.25101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ppul.25101","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.25101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:56:15Z","timestamp":1693702575000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.25101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1002\/ppul.25101"],"URL":"https:\/\/doi.org\/10.1002\/ppul.25101","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"value":"8755-6863","type":"print"},{"value":"1099-0496","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"2020-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}